{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T18:22:45Z","timestamp":1794939765436,"version":"4.9.1"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T00:00:00Z","timestamp":1640131200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,7,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background and Aims<\/jats:title>\n                  <jats:p>Subcutaneous [SC] vedolizumab presents the opportunity for inflammatory bowel disease [IBD] patients to manage their treatment at home. There are currently no data on the process of transitioning patients established on intravenous [IV] to SC vedolizumab as part of routine clinical care. The aim of this programme is to evaluate the clinical and biochemical outcomes of switching a cohort of IBD patients established on IV vedolizumab to SC, at 12 weeks following the transition.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In all, 178 adult patients were offered the opportunity to transition to SC vedolizumab. Patients who agreed were reviewed prior to switching and at Week 12 [W12] after their first SC dose. Evaluation outcomes included disease activity scores, the IBD-Control Patient-Reported Outcome Measures [PROMs], and faecal calprotectin [FCP]. Reasons for patients declining or accepting transitioning, pharmacokinetics, adverse drug reactions, and risk factors for a poor outcome in SARS-CoV-2 infection were also assessed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 124 patients agreed to transition, of whom 106 patients had been on IV vedolizumab for at least 4 months. There were no statistically significant differences in disease activity scores or IBD-Control PROMs between baseline and W12. A statistically significant increase in FCP was observed [31 \u00b5g\/g vs. 47 \u00b5g\/g; p = 0.008], although this was unlikely to be clinically relevant. The most common adverse drug reaction reported was injection site reactions [15%]. Based on this cohort of patients, an expected reduction of \u00a3572,000 per annum is likely to be achieved.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Transitioning patients established on IV vedolizumab to SC appears to be safe and effective, with high patient satisfaction and multiple benefits for the health service.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjab224","type":"journal-article","created":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T20:29:57Z","timestamp":1640032197000},"page":"911-921","source":"Crossref","is-referenced-by-count":51,"title":["Transitioning from Intravenous to Subcutaneous Vedolizumab in Patients with Inflammatory Bowel Disease [TRAVELESS]"],"prefix":"10.1093","volume":"16","author":[{"given":"Esther","family":"Ventress","sequence":"first","affiliation":[{"name":"Pharmacy Department, University Hospital Southampton NHS Foundation Trust [UHS], Southampton , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Young","sequence":"additional","affiliation":[{"name":"Pharmacy Department, University Hospital Southampton NHS Foundation Trust [UHS], Southampton , UK"},{"name":"Faculty of Medicine, University of Southampton, Southampton , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sohail","family":"Rahmany","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, University Hospital Southampton NHS Foundation Trust, Southampton , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare","family":"Harris","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Southampton, Southampton , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Bettey","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, University Hospital Southampton NHS Foundation Trust, Southampton , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, University Hospital Southampton NHS Foundation Trust, Southampton , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Moyses","sequence":"additional","affiliation":[{"name":"NIHR Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Lech","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Southampton, Southampton , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Gwiggner","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, University Hospital Southampton NHS Foundation Trust, Southampton , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Felwick","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, University Hospital Southampton NHS Foundation Trust, Southampton , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J R Fraser","family":"Cummings","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Southampton, Southampton , UK"},{"name":"Department of Gastroenterology, University Hospital Southampton NHS Foundation Trust, Southampton , UK"},{"name":"NIHR Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,12,22]]},"reference":[{"key":"2022071420383461000_CIT0001","author":"Takeda UK Ltd","year":"2020"},{"key":"2022071420383461000_CIT0002","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/gutjnl-2018-316023","article-title":"Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease","volume":"68","author":"Zeissig","year":"2019","journal-title":"Gut"},{"key":"2022071420383461000_CIT0003","author":"National Institute for Health and Care Excellence","year":"2015"},{"key":"2022071420383461000_CIT0004","author":"National Institute for Health and Care Excellence","year":"2015"},{"key":"2022071420383461000_CIT0005","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1136\/gutjnl-2020-322539","article-title":"Effect of IBD medications on COVID-19 outcomes: results from an international registry","volume":"70","author":"Ungaro","year":"2021","journal-title":"Gut"},{"key":"2022071420383461000_CIT0006","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1136\/gutjnl-2020-321244","article-title":"British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic","volume":"69","author":"Kennedy","year":"2020","journal-title":"Gut"},{"key":"2022071420383461000_CIT0007","author":"NHS England","year":"2019"},{"key":"2022071420383461000_CIT0008","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s10067-017-3587-8","article-title":"Are abatacept and tocilizumab intravenous users willing to switch for the subcutaneous route of administration? A questionnaire-based study","volume":"36","author":"Desplats","year":"2017","journal-title":"Clin Rheumatol"},{"key":"2022071420383461000_CIT0009","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.breast.2015.01.002","article-title":"Implications of subcutaneous or intravenous delivery of trastuzumab; further insight from patient interviews in the PrefHer study","volume":"24","author":"Fallowfield","year":"2015","journal-title":"Breast"},{"key":"2022071420383461000_CIT0010","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s40271-014-0075-y","article-title":"Intravenous versus subcutaneous drug administration. Which do patients prefer? A systematic review","volume":"8","author":"Stoner","year":"2015","journal-title":"Patient"},{"key":"2022071420383461000_CIT0011","first-page":"S417","article-title":"S0812 patients\u2019 preferences for subcutaneous or intravenous administration methods in inflammatory bowel diseases","volume":"115","author":"Van Deen","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"2022071420383461000_CIT0012","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1053\/j.gastro.2020.02.030","article-title":"Efficacy of upadacitinib in a randomized trial of patients with active ulcerative colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"2022071420383461000_CIT0013","doi-asserted-by":"crossref","first-page":"S020","DOI":"10.1093\/ecco-jcc\/jjz203.022","article-title":"OP23 Efficacy and safety of vedolizumab SC in patients with moderately to severely active Crohn\u2019s disease: results of the VISIBLE 2 study","volume":"14","author":"Vermeire","year":"2020","journal-title":"J Crohns Colitis"},{"key":"2022071420383461000_CIT0014","author":"Takeda UK Ltd","year":"2021"},{"key":"2022071420383461000_CIT0015","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0140-6736(80)92767-1","article-title":"A simple index of Crohn\u2019s-disease activity","volume":"1","author":"Harvey","year":"1980","journal-title":"Lancet"},{"key":"2022071420383461000_CIT0016","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/gut.43.1.29","article-title":"A simple clinical colitis activity index","volume":"43","author":"Walmsley","year":"1998","journal-title":"Gut"},{"key":"2022071420383461000_CIT0017","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1136\/gutjnl-2013-305600","article-title":"Development and validation of a rapid, generic measure of disease control from the patient\u2019s perspective: the IBD-control questionnaire","volume":"63","author":"Bodger","year":"2014","journal-title":"Gut"},{"key":"2022071420383461000_CIT0018","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/MIB.0000000000000652","article-title":"Low fecal calprotectin correlates with histological remission and mucosal healing in ulcerative colitis and colonic Crohn\u2019s disease","volume":"22","author":"Zittan","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"2022071420383461000_CIT0019","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s40744-016-0041-3","article-title":"Randomized crossover comparison of injection site pain with 40 mg\/0.4 or 0.8 mL formulations of adalimumab in patients with rheumatoid arthritis","volume":"3","author":"Nash","year":"2016","journal-title":"Rheumatol Ther"},{"key":"2022071420383461000_CIT0020","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med"},{"key":"2022071420383461000_CIT0021","author":"National Institute for Health and Care Excellence","year":"2016"},{"key":"2022071420383461000_CIT0022","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S2468-1253(20)30392-7","article-title":"From intravenous to subcutaneous infliximab in patients with inflammatory bowel disease: a pandemic-driven initiative","volume":"6","author":"Verma","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2022071420383461000_CIT0023","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-230X-10-1","article-title":"How do patients with inflammatory bowel disease want their biological therapy administered?","volume":"10","author":"Allen","year":"2010","journal-title":"BMC Gastroenterol"},{"key":"2022071420383461000_CIT0024","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1002\/ibd.21888","article-title":"Systematic assessment of factors influencing preferences of Crohn\u2019s disease patients in selecting an anti-tumor necrosis factor agent [CHOOSE TNF TRIAL]","volume":"18","author":"Vavricka","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"2022071420383461000_CIT0025","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s40744-020-00245-0","article-title":"Understanding and minimising injection-site pain following subcutaneous administration of biologics: a narrative review","volume":"7","author":"St Clair-Jones","year":"2020","journal-title":"Rheumatol Ther"},{"key":"2022071420383461000_CIT0026","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/apt.15113","article-title":"Vedolizumab exposure levels and clinical outcomes in ulcerative colitis: determining the potential for dose optimisation","volume":"49","author":"Osterman","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"2022071420383461000_CIT0027","doi-asserted-by":"crossref","first-page":"S357","DOI":"10.1093\/ecco-jcc\/jjy222.614","article-title":"P490 A vedolizumab population pharmacokinetic model including intravenous and subcutaneous formulations for patients with ulcerative colitis","volume":"13","author":"Rosario","year":"2019","journal-title":"J Crohns Colitis"},{"key":"2022071420383461000_CIT0028","doi-asserted-by":"crossref","first-page":"e001570","DOI":"10.1136\/bmjopen-2012-001570","article-title":"A systematic review of evidence on the links between patient experience and clinical safety and effectiveness","volume":"3","author":"Doyle","year":"2013","journal-title":"BMJ Open"},{"key":"2022071420383461000_CIT0029","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1136\/gutjnl-2012-303376","article-title":"Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNF\u03b1 therapy: results from the COIN study","volume":"63","author":"van der Valk","year":"2014","journal-title":"Gut"},{"key":"2022071420383461000_CIT0030","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/MCG.0b013e3182732ff5","article-title":"Mucosal healing in inflammatory bowel disease","volume":"47","author":"Osterman","year":"2013","journal-title":"J Clin Gastroenterol"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjab224\/42387154\/jjab224.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/16\/6\/911\/44890536\/jjab224.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/16\/6\/911\/44890536\/jjab224.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T20:40:12Z","timestamp":1657831212000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/16\/6\/911\/6478741"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,22]]},"references-count":30,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,12,22]]},"published-print":{"date-parts":[[2022,7,14]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjab224","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,6,1]]},"published":{"date-parts":[[2021,12,22]]}}}